Anacor Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase 3 Trials of AN2690 for Onychomycosis  
11/10/2011 6:21:49 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has completed enrollment in the first of two Phase 3 trials of tavaborole (formerly known as AN2690), a topical anti-fungal product candidate for the treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.